Simplified Human Immunodeficiency Virus Maintenance Therapy in Virologically Suppressed Children With Ritonavir-boosted Protease Inhibitor Monotherapy

2011 ◽  
Vol 30 (10) ◽  
pp. 917 ◽  
Author(s):  
Olaf Neth ◽  
Lola Falcon-Neyra ◽  
Rosa Ruiz-Valderas ◽  
Jose Antonio León Leal ◽  
Ignacio Obando ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Maintenance Therapy ◽  
Protease Inhibitor ◽  
Immunodeficiency Virus ◽  
Protease Inhibitor Monotherapy

scholarly journals Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract

2016 ◽  
Vol 22 (1) ◽  
pp. 98.e7-98.e10 ◽  
Author(s):  
A. Torres-Cornejo ◽  
O.J. BenMarzouk-Hidalgo ◽  
P. Viciana ◽  
B. Sánchez ◽  
M.A. López-Ruz ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Genital Tract ◽  
Male Genital Tract ◽  
Immunodeficiency Virus ◽  
Protease Inhibitor Monotherapy ◽  
Human Immunodeficiency Virus 1 ◽  
Male Genital

scholarly journals Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus–positive Patients Treated With Protease Inhibitor Monotherapy

2018 ◽  
Vol 68 (6) ◽  
pp. 1031-1040 ◽  
Author(s):  
Lewis J Haddow ◽  
Claudia Godi ◽  
Magdalena Sokolska ◽  
M Jorge Cardoso ◽  
Ruth Oliver ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cognitive Function ◽  
Protease Inhibitor ◽  
Brain Perfusion ◽  
Immunodeficiency Virus ◽  
Protease Inhibitor Monotherapy

Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor.

1995 ◽  
Vol 69 (4) ◽  
pp. 2148-2152 ◽  
Author(s):  
A K Patick ◽  
R Rose ◽  
J Greytok ◽  
C M Bechtold ◽  
M A Hermsmeier ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus

scholarly journals Elevated Levels of Estradiol in Human Immunodeficiency Virus–Infected Pregnant Women on Protease Inhibitor–Based Regimens

2017 ◽  
Vol 66 (3) ◽  
pp. 420-427 ◽  
Author(s):  
Kayode A Balogun ◽  
Monica S Guzman Lenis ◽  
Eszter Papp ◽  
Mona Loutfy ◽  
Mark H Yudin ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Pregnant Women ◽  
Immunodeficiency Virus

scholarly journals Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro

2003 ◽  
Vol 47 (10) ◽  
pp. 3123-3129 ◽  
Author(s):  
Yasuhiro Koh ◽  
Hirotomo Nakata ◽  
Kenji Maeda ◽  
Hiromi Ogata ◽  
Geoffrey Bilcer ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Therapeutic Agent ◽  
Close Contact ◽  
Wide Spectrum ◽  
Antiviral Agents ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC50], ∼0.003 μM; IC90, ∼0.009 μM) with minimal cytotoxicity (50% cytotoxic concentration for CD4+ MT-2 cells, 74 μM). UIC-94017 blocked the infectivity and replication of each of HIV-1NL4-3 variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 μM (IC50s, 0.003 to 0.029 μM), although it was less active against HIV-1NL4-3 variants selected for resistance to amprenavir (IC50, 0.22 μM). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections.

scholarly journals Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection

2017 ◽  
Vol 9 (4) ◽  
pp. 217 ◽  
Author(s):  
Kenneth E Sherman ◽  
Minhee Kang ◽  
Richard Sterling ◽  
Triin Umbleja ◽  
Kristen Marks ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Protease Inhibitor ◽  
First Generation ◽  
Inhibitor Therapy ◽  
Protease Inhibitor Therapy ◽  
Phase 3 ◽  
Immunodeficiency Virus

scholarly journals The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin

2011 ◽  
Vol 6 (4) ◽  
pp. 661-670 ◽  
Author(s):  
Anjaiah Srirangam ◽  
Monica Milani ◽  
Ranjana Mitra ◽  
Zhijun Guo ◽  
Mariangellys Rodriguez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Cancer Cells ◽  
Lung Cancer Cells ◽  
Human Immunodeficiency Virus Protease ◽  
Immunodeficiency Virus
Sign in / Sign up

Export Citation Format

Share Document